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The study of successful versus failed zoonotic infectionsmay provide important clues of how viral infection is
naturally prevented. In this issue of Cell Host & Microbe, a collaborative group led by Frank Kirchhoff
uncovers an important piece of the pandemic HIV-1 puzzle.Phylogenetic analyses indicate that HIV-1
arose from a zoonotic infection from chim-
panzees. Moreover, HIV-1 has been trans-
mitted to humans on at least three separate
occasions, and each of those zoonotic
events has given rise to an independent
group of HIV-1 sequences referred to as
HIV-1 M (main), O (outlier), and N (non-M,
non-O).Remarkably, the frequencyof these
viruses in the current human population is
vastly different, with around 30 million
people living with HIV-1 M group infection
and about 10,000 with O group infection.
Only a handful of N group infections have
ever been described. Thus, O and N group
viruses are not pandemic, and in the
absence of HIV-1 M group infections, HIV/
AIDS would be a rare tropical disease.
It is obviously of great importance to under-
stand the differences between the viruses
that underlie their different frequencies.
What are the features of pandemic HIV-1
that make it so much more successful?
Now, Sauter and colleagues show that,
although pandemic HIV-1 M group has
successfully adapted its Vpu protein to
antagonize the human antiviral restriction
factor tetherin, the O group viruses have
not. Could the ability to escape tetherin
explain the different frequencies of pan-
demic and nonpandemic HIV-1 strains?
Mammalian cells encode interferon-
inducible antiviral restriction factors as a
means of protecting themselves from viral
infection. The recently identified BST-2/
CD317/HM1.24/tetherin (Neil et al., 2008;
Van Damme et al., 2008) is an excellent
example of one such protein that can
restrict infectivity of retroviruses, filovi-
ruses, and arena viruses. Tetherin has
an N-terminal extracellular domain, a
C-terminal GPI anchor, and a coiled coil
in the middle that promotes dimerization(Figure 1). It is thus attached to the cell
membrane at each end, and tetherin
dimers are proposed to form a protein
tether linking assembled virions to in-
fected cells, leading to their endocytosis
and degradation in lyzosomes (Neil et al.,
2008;VanDammeetal., 2008). Two recent
studies use electronmicroscopy and teth-
erin mutagenesis to show that it is prob-
ably tetherin itself that forms the tether
between the virus and the cell membrane
(Fitzpatrick et al., 2009; Perez-Caballero
et al., 2009). Perez-Cabellero and col-
leagues elegantly demonstrate the sim-
plicity of the tethering mechanism by
generating an artificial tetherin with full
activity by fusing a transmembrane region
to a coiled coil with a GPI anchor at the C
terminus. Although this artificial molecule
had no sequence similarity to tetherin,
tethered virions observed by electron
microscopy appeared similar to those
tethered by tetherin (Perez-Caballero
et al., 2009). Fitzpatrick and colleagues
use electron microscopy and antitetherin
labeling to show that tetherin appears in
the virion tethers and in the membrane of
the few released virions that manage to
escape (Fitzpatrick et al., 2009). These
two studies favor different possibilities
regarding the configuration of the tetherin
dimers that constitute the tethers (Fig-
ure 1), but we predict that it will be difficult
to rule out the possibility that tetherin can
effectively tether in more than one config-
uration.
In order to replicate in cells that express
tetherin, primate lentiviruses encode
accessory proteins Vpu and Nef that
specifically antagonize tetherin (Jia et al.,
2009; Neil et al., 2008; Sauter et al.,
2009; Zhang et al., 2009). It appears that
a virus can have one or more tetherinCell Host & Microbe 6, Nantagonists, either Vpu or Nef, or even
the envelope glycoprotein. Recent data
demonstrate that the envelope glycopro-
teins from HIV-2 and Tantalus monkey
SIV antagonize tetherin by sequestration
in the Trans Golgi Network (TGN) (Gupta
et al., 2009; Le Tortorec and Neil, 2009).
It is not yet clear how Nef antagonizes
tetherin, but HIV-1 Vpu leads to tetherin
degradation. Importantly, tetherin shows
evidence of positive (adaptive) selection
(McNatt et al., 2009), presumably as a
result of evolutionary pressure applied
by antagonistic viral proteins that coun-
teract its inhibition of viral replication.
This has led to the species-specific teth-
erin sensitivity to viral countermeasures.
For example, Tantalus monkey tetherin
cannot be abrogated by HIV-1 Vpu due
to variation in the tetherin transmembrane
region (McNatt et al., 2009). Similarly,
SIV Nefs are able to overcome simian
tetherins, but not human tetherin, due to
sequence variation in the cytoplasmic
tail of tetherin (Jia et al., 2009; McNatt
et al., 2009; Sauter et al., 2009; Zhang
et al., 2009).
So how do the various HIV-1 and chim-
panzee SIV (SIVcpz) strains compare in
their ability to antagonize tetherin? Sauter
and colleagues show that, like a variety of
SIVs, SIVcpz uses Nef to antagonize teth-
erin. Aswenowknow fromseveral studies,
HIV-1 uses its Vpu protein (McNatt et al.,
2009; Neil et al., 2008). This suggests that
SIVcpz-derived HIV-1 has had to adapt
its Vpu inorder to effectively transmit tohu-
mans. However, adaptation to use Vpu to
antagonize tetherin has not been achieved
by the significantly less prevalent HIV-1 O
group viruses. Adaptation was required
due to sequence variation between the
various tetherin proteins. Importantly, theovember 19, 2009 ª2009 Elsevier Inc. 393
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Previewshuman tetherin protein uniquely has a 4
amino acid deletion in its cytoplasmic tail
that makes it insensitive to Nef from a
variety of SIVs, including SIVcpz (Sauter
et al., 2009; Zhang et al., 2009). Replacing
these amino acids makes human tetherin
almost fully sensitive to antagonism by
SIVcpz Nef and moderately sensitive to
O group Nefs (Sauter et al., 2009). We
suggest that the tetherin tail deletion was
selected by previous encounters with viral
antagonists, perhaps even Nef/Vpu-like
molecules from long-lost infections. The
high level of relatedness between humans
and chimpanzees has led us to believe
that the species barriers to zoonotic viral
infection between chimpanzees and
humans are rather low. This is the first
example of an adaptation made by HIV-1
to improve replication in humans or
human-human transmission. The differ-
ence in prevalence between M and O
suggests that this adaptation has been
critical for the establishment of the human
pandemic. The chimp-human species
barrier may be low, but tetherin seems to
have made an important contribution by
virtue of the loss of 4 amino acids in its
cytoplasmic tail.
What of N group virus’ ability to antago-
nize tetherin? N group infections are
extremely rare; fewer than 20 have ever
been described. Sauter and colleagues
tested Vpu from three N group viruses
and found that one of them antagonized
tetherin quite well, whereas the other
two did so but rather poorly. It is hard to
conclude that N group Vpus can generally
antagonize tetherin from these observa-
tions, but certainly, N group Vpus are
better at this than are O group Vpus. On
the other hand, the N group Vpus were
unable to downregulate cell surface
expression of the T cell receptor CD4.
This is thought to be a critical Vpu func-
tion that is essential for preventing super-
infection and facilitating infectious viral
release. These observations suggest that
N group viruses may have other problems
or at least have alternate, perhaps less
effective, strategies for manipulating their
new human host.
Does the relative success or failure of
these host virus interactions have an
impact on disease? This is hard to say,
but there is little evidence that they do.
O and M group infections appear to lead
to similarly high frequencies of clinical
AIDS, high plasma viral loads, and similar
frequencies of mother-to-child trans-
missions. Furthermore, rhesus macaque
SIV with a human Nef gene, which is ap-
parently unable to antagonize rhesus
tetherin, can cause disease in rhesus
macaques, although it is less pathogenic.
Thus, the ability to antagonize tetherin
may be more important for transmission
than pathogenesis. However, more work
is required, and we propose that the
continued comparison of the molecular
details of host virus interactions between
common and rare types of HIV and their
hosts will reveal important information.
The central message from Sauter’s
important study is that SIVcpz-derived
HIV-1 has switched fromusingNef to using
Vpu to counteract tetherin during zoonosis
from chimpanzees to humans. It appears
that this change may have made a signifi-
cant contribution to its ability to spread
through the human population. Impor-
tantly, primate lentivirusesdistantly related
to HIV-1, such as SIVgsn, SIVmus, and
SIVmon, also use Vpu to antagonize teth-
erin, suggesting that primate lentiviruses
have switched which proteins they use to
antagonize tetherin on several occasions.
We are reminded of the plasticity of lentivi-
ral protein function and the power of selec-
tive pressure. The Red Queen hypothesis
suggests an ongoing evolutionary conflict
between hosts and their pathogens, and
in this case, we have a vivid example of
how tetherin and primate lentiviruses
have swapped the advantage throughout
their evolution. Currently, HIV-1 M group
appears to have the lead.
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Figure 1. Models for Tetherin’s Antiretroviral Tethering Activity
Tetherin restricts retroviral release by tethering newly formed virions to the cell surface. The protease-
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erin protein configurations. Currently, Perez-Caballero et al. (2009) and Fitzpatrick et al. (2009) favor
different models, but we expect that it will be difficult to rule out the existence of more than one of these
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CPXV12 is the first poxvirus gene p
processing (TAP). This cowpox viru
ciently suppress MHC class I antige
2010 marks the 30th anniversary of the
global eradication of smallpox, a remark-
able achievement that began on May
14th, 1796, when Edward Jenner (Figure 1)
inoculated James Phipps with live cow-
pox virus from the hand of a milkmaid,
Sarah Nelmes, and subsequently showed
the boy to be immune to smallpox. This
experiment not only laid the foundation
for the global eradication of smallpox,
but also established vaccination (Latin
vacca, for cow) as a means of generating
a protective immune response. The pro-
tective immunity elicited by orthopoxvi-
ruses is thought to involve both humoral
and cellular components of the adaptive
immune system (Dasgupta et al., 2007).
Two papers in this issue of Cell Host &
Microbe now identify a second cowpox
virus (CPXV) gene product that downre-
gulates major histocompatibility complex
class I (MHC class I) molecules and con-
founds the adaptive cellular immune
response (Alzhanova et al., 2009; Byun
et al., 2009).
Downregulation of MHCclass I was first
identified in adenovirus (E3-19K) and is
now recognized as a major immune strat-
egy for many viruses, including HIV (Han-
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roduct demonstrated to inhibit the t
s function acts in concert with a seco
n presentation and enhance in vivo
surface MHC class I expression will pre-
vent specific viral peptides from being
presented to cytotoxic T lymphocytes
(CTLs) and therefore promote immune
evasion. In recent years, the field has
been dominated by studies on herpesvi-
ruses. An impressive array of herpesviral
gene products target multiple stages in
the MHC class I antigen presentation
pathway, including peptide generation
by proteasomes, TAP-mediated transport
of peptides into the ER, and the retention
or ER-associated degradation of newly
synthesized MHC class I heavy chain.
Once formed, the heterotrimeric complex
of MHC class I heavy chain, b2-microglo-
bulin, and peptide traffics to the cell
surface, but may yet be arrested in the
secretory pathway or removed from the
cell surface by ubiquitination and endo-
cytosis.
Interest is now growing in the capacity
of poxviruses to actively evade the cellular
immune response (Guerin et al., 2002;
Campbell et al., 2007; Hammarlund et al.,
2008). The research group headed by
Klaus Fru¨h first demonstrated that CPXV
inhibits MHC class I trafficking, while
Wayne Yokoyama’s laboratory identified
the CPXV203 gene product as respon-
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nd gene product, CPXV203, to effi-
virulence.
sible for ER retention of newly synthesized
MHC class I. However, when CPXV203
was deleted from the virus, it was clear
that CPXV encoded a second MHC class
I evasion function capable of acting
independently. Both groups now identify
this second function to be encoded by
CPXV12 and, in complementary studies,
go on to investigate its mechanism of
action and role in evading CD8+ cytotoxic
T cells (Figure 1).
The two groups came to CPXV12 from
opposite directions. Yokoyama’s group
performed a series of iterative deletions
in the CPXV genome to ultimately map
the gene by loss-of-function in the virus
(Byun et al., 2009), whereas Fru¨h’s group
interrogated a panel of potential candi-
dates in transient gain-of-function assays
(Alzhanova et al., 2009). In the prototype
BR strain, CPXV12 encodes a 69 amino
acid (8.5 kDa) type II membrane protein
that localizes to the ER. In vitro expression
studies using microsomal extracts are
consistent with the protein consisting of
anN-terminalmembrane-spanning region
with the C terminus extruding into the
lumen of the ER (Alzhanova et al., 2009).
To get a handle on CPXV12, the protein
was expressed with an epitope tag and
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